EGLN3 and hepatocellular carcinoma: Therefore, CHGA, EGLN3, and CFHR3 were used to establish a predictive signature for patients with HCC in TCGA training cohort with a risk score of (0.101109253 × CHGA expression) + (0.116251865 × EGLN3 expression) + (–0.094009858 × CFHR3 expression).